Kevin Farr compensation by year
Niagen Bioscience Summary Compensation Table · all 6 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Salary | $60,000 | $300,000 | $306,577 | $320,884 | $309,000 | $197,975 |
| Bonus | $24,378 | $93,600 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $150,729 |
| Option awards | $3,040,183 | $0 | $210,450 | $209,217 | $215,808 | $215,697 |
| Non-equity incentive | $0 | $0 | $98,058 | $149,507 | $92,253 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $6,418 | $9,208 | $9,368 | $275,136 |
| Total | $3,124,561 | $393,600 | $621,503 | $688,816 | $626,429 | $839,537 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Niagen Bioscience, Inc. DEF 14A filed April 28, 2023, accession 0001628280-23-014158, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Niagen Bioscience, Inc. filed document, accession 0001628280-23-014158. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.
Niagen Bioscience’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Robert Fried | Chief Executive Officer | $1,158,850 |
| Brianna Gerber | Chief Financial Officer | $842,384 |
| Kevin Farr · this page | Former Chief Financial Officer | $839,537 |
| Frank Jaksch Jr. | Former Executive Chairman, Current Chairman of the Board | $482,354 |
The full Niagen Bioscience compensation record
free company briefThis page is one person within Niagen Bioscience's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Niagen Bioscience's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.